LAG3 and diffuse large B-cell lymphoma: Across cancer types profiled in The Cancer Genome Atlas and confirmed by IHC in this study, LAG-3 expression in DLBCL was among the highest described, emphasizing a potential role for anti-LAG-3 immunotherapy62.